- Details
- In 2019 the first interim analysis of the phase III TITAN trial was reported which led to the approval of apalutamide for metastatic castration-sensitive prostate cancer (mCSPC). In this conversation with Alicia Morgans, MD, MPH, Neeraj Agarwal, MD highlights the final overall survival analysis after a median follow-up of 44 months (nearly 4-years) and the recent final survival analysis Journal of...
|
- Details
- Matthew Deek and Phuoc Tran join Charles Ryan to discuss their recent paper "The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited" published in European Urology. The aim of this study was to characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biologi...
|
- Details
- Michael Morris, MD, and Christopher Sweeney, MBBS join Alicia Morgans, MD, MPH in a discussion on the treatment of metastatic hormone-sensitive prostate cancer. Dr. Sweeney shares his perspective on the use of combination therapy, in addition to traditional ADT, and how he approaches treatment decisions Dr. Morris discusses the latest data in this space coming from the CHAARTED and STAMPEDE studie...
|
- Details
- Tom Keane welcomes Evan Yu to discuss the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. Dr. Yu details the most crucial studies to date demonstrating improved OS in mHSPC patients, including the ARCHES , ENZAMET , STAMPEDE , and TITAN clinical trials. Additionally, he touches on the survival benefit shown in the CHAARTED trial. Dr. Yu provides a compreh...
|
- Details
- Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to imp...
|
- Details
- Christopher Sweeney joins Charles Ryan to discuss the topic of hormone-sensitive prostate cancer, specifically concentrating on how clinicians can confront and categorize their patients with the disease. In continuing the ongoing conversation of the optimal approach for a high-volume patient, Dr. Sweeney uses evidence from current clinical trials to outline optional alternatives to abiraterone tre...
|
- Details
- Nick James, a Professor of Clinical Oncology at the Institute of Cancer Research joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses the developments around the high-volume/low-volume disease in metastatic hormone-sensitive disease from the STAMPEDE trial. They also discuss relapsed disease versus de novo metastatic disease. Biographies: P...
|
- Details
- Kenneth Pienta joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019) to discuss the biology of prostate cancer, and to share a clinician's perspective of thinking about the biology of this disease. This is a look at the current year and some of the significant findings that have changed the way we look at treating prostate cancer. The STAMPEDE data sho...
|
- Details
- In this conversation with Alicia Morgans, Matthew Smith shares highlights from his 2019 European Society for Medical Oncology annual meeting, (ESMO) presentation. He presented the updated survival results from SPARTAN, A study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (nmCRPC), a pivotal study which led to the approval of apalutamide for men with nmCR...
|
- Details
- In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...
|
